FROEDTERT MEMORIAL LUTHERAN HOS
9200 W WISCONSIN AVE
July 04, 2014
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.